Journal de mycologie medicale最新文献

英文中文

Head skin infection by Candida auris: A case report 耳念珠菌感染头部皮肤1例

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale

Pub Date : 2025-03-18 DOI: 10.1016/j.mycmed.2025.101544

Jueting Tang, Kaiying Yang, Zhixin Cui, Yanhong Guan, Zelun Li

Background

Candida auris is a recently discovered yeast species first found in 2009 in the ear discharge of a patient in Japan. Known for its high mortality rate, strong transmissibility, ability to cause hospital outbreaks, and resistance to multiple drugs, it has earned the nickname "superbug". Currently, there are five main clades of Candida auris identified, including the South Asian, East Asian, South African, South American, and a newly discovered fifth clade in Iran. Infection cases have been documented in over 40 countries across six continents, drawing global attention. In 2022, the World Health Organization (WHO) designated Candida auris as a top priority pathogen in their inaugural list of fungal threats to health. The lack of standardized and effective treatment protocols and prevention strategies has resulted in numerous treatment and control failures. To delve deeper into the clinical management strategies and hospital infection control measures for Candida auris, we conducted a retrospective analysis of a Candida auris infection case and briefly reviewed relevant literature.

Case presentation

A 54-year-old male patient with a complex medical history developed a Candida auris infection, presenting with ulcerative scalp lesions. The medical team implemented local wound care measures, including iodophor disinfection and infrared therapy, and strictly adhered to the hospital's infection control protocols, successfully controlling the Candida auris infection without any nosocomial transmission.

Conclusion

This case study highlights the importance of individualized treatment and tailored infection control measures implemented through interdisciplinary teamwork. The successful management underscores the potential for containing the spread of Candida auris, offering valuable insights for future strategies against this emerging multidrug-resistant pathogen. However, the complex challenges in diagnosing, treating, and controlling Candida auris infections emphasize the imperative need to enhance research and establish standardized protocols.

背景耳念珠菌是一种新发现的酵母菌，于2009年在日本一名患者的耳分泌物中首次发现。它以其高死亡率、强传染性、能引起医院爆发和对多种药物具有耐药性而闻名，因此获得了“超级细菌”的绰号。目前，已确定的念珠菌有五个主要分支，包括南亚、东亚、南非、南美，以及在伊朗新发现的第五个分支。在六大洲的40多个国家记录了感染病例，引起了全球关注。2022年，世界卫生组织（世卫组织）在其首份真菌健康威胁清单中将耳念珠菌指定为最优先的病原体。由于缺乏标准化和有效的治疗方案和预防战略，导致许多治疗和控制失败。为了深入探讨耳念珠菌的临床管理策略和医院感染控制措施，我们对1例耳念珠菌感染病例进行回顾性分析，并简要复习相关文献。病例表现：54岁男性患者，病史复杂，并发耳念珠菌感染，表现为头皮溃疡性病变。医疗队实施局部伤口护理措施，包括碘伏消毒和红外线治疗，并严格遵守医院感染控制方案，成功控制了耳念珠菌感染，无院内传播。结论本病例研究强调了通过跨学科团队合作实施个性化治疗和量身定制的感染控制措施的重要性。成功的管理强调了遏制金黄色念珠菌传播的潜力，为今后针对这种新出现的多重耐药病原体的战略提供了有价值的见解。然而，在诊断、治疗和控制耳念珠菌感染方面的复杂挑战强调了加强研究和建立标准化方案的迫切需要。

{"title":"Head skin infection by Candida auris: A case report","authors":"Jueting Tang, Kaiying Yang, Zhixin Cui, Yanhong Guan, Zelun Li","doi":"10.1016/j.mycmed.2025.101544","DOIUrl":"10.1016/j.mycmed.2025.101544","url":null,"abstract":"<div><h3>Background</h3><div><em>Candida auris</em> is a recently discovered yeast species first found in 2009 in the ear discharge of a patient in Japan. Known for its high mortality rate, strong transmissibility, ability to cause hospital outbreaks, and resistance to multiple drugs, it has earned the nickname \"superbug\". Currently, there are five main clades of <em>Candida auris</em> identified, including the South Asian, East Asian, South African, South American, and a newly discovered fifth clade in Iran. Infection cases have been documented in over 40 countries across six continents, drawing global attention. In 2022, the World Health Organization (WHO) designated <em>Candida auris</em> as a top priority pathogen in their inaugural list of fungal threats to health. The lack of standardized and effective treatment protocols and prevention strategies has resulted in numerous treatment and control failures. To delve deeper into the clinical management strategies and hospital infection control measures for Candida auris, we conducted a retrospective analysis of a <em>Candida auris</em> infection case and briefly reviewed relevant literature.</div></div><div><h3>Case presentation</h3><div>A 54-year-old male patient with a complex medical history developed a <em>Candida auris</em> infection, presenting with ulcerative scalp lesions. The medical team implemented local wound care measures, including iodophor disinfection and infrared therapy, and strictly adhered to the hospital's infection control protocols, successfully controlling the <em>Candida auris</em> infection without any nosocomial transmission.</div></div><div><h3>Conclusion</h3><div>This case study highlights the importance of individualized treatment and tailored infection control measures implemented through interdisciplinary teamwork. The successful management underscores the potential for containing the spread of Candida auris, offering valuable insights for future strategies against this emerging multidrug-resistant pathogen. However, the complex challenges in diagnosing, treating, and controlling <em>Candida auris</em> infections emphasize the imperative need to enhance research and establish standardized protocols.</div></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"35 2","pages":"Article 101544"},"PeriodicalIF":2.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disseminated infection with Candida dubliniensis after ravulizumab and treatment with rezafungin – a case report 拉乌利珠单抗治疗后弥散性dubliniensis感染- 1例报告

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale

Pub Date : 2025-03-16 DOI: 10.1016/j.mycmed.2025.101545

Felix Lötsch , Michael Eder , Haris Omic , Konstantin Doberer , Martina Scharitzer , Matthias G. Vossen , Gabriella Muraközy , Birgit Willinger , Christof Aigner

引用次数: 0

Fungal microbiota in COPD patients during exacerbations 慢性阻塞性肺病患者加重期的真菌微生物群

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale

Pub Date : 2025-03-10 DOI: 10.1016/j.mycmed.2025.101543

Weronika Gawor , Katarzyna Góralska , Sandra Galant , Sebastian Majewski , Wojciech Piotrowski , Joanna Miłkowska-Dymanowska , Justyna Kiszałkiewicz , Ewa Brzeziańska-Lasota

Acute exacerbations of chronic obstructive pulmonary disease (COPD) results in increased mortality and can be triggered by a range of factors, including microorganisms. Very little studies have examined the role of fungi and fungal diversity in COPD patients. The aim of the study was to determine the role of Candida in COPD during an exacerbation. Oral swabs, sputum, feces and whole blood samples were collected from the AECOPD patients and control group. Mycological and serological analysis were performed. Yeast were statistically significantly more often isolated from the AECOPD group (97.06%) than from the control group (26.32%). 7 species were isolated from the AECOPD, and 3 from the control group. Dominated Candida albicans followed by C. tropicalis. α-diversity was much greater in AECOPD patients than in controls. β-diversity was also assessed. A much higher level of antimycotic resistance was observed in isolates from the AECOPD group, which affects the effectiveness of therapy. Serological tests showed twice the frequency of positive results in the AECOPD group. The mycobiota of AECOPD patients is numerically and taxonomically richer than controls, including species less frequently recorded in humans. Our research confirms that fungal mycobiota may be a potential factor influencing the development of exacerbations and progression of COPD.

慢性阻塞性肺疾病（COPD）的急性加重可导致死亡率增加，并可由包括微生物在内的一系列因素引发。很少有研究检查真菌和真菌多样性在COPD患者中的作用。该研究的目的是确定念珠菌在COPD加重期间的作用。收集AECOPD患者和对照组的口腔拭子、痰、粪便和全血样本。进行真菌学和血清学分析。AECOPD组酵母菌分离率（97.06%）显著高于对照组（26.32%）。从AECOPD中分离到7种，从对照组中分离到3种。以白色念珠菌为主，其次为热带念珠菌。α-多样性在AECOPD患者中明显高于对照组。还对β-多样性进行了评估。在AECOPD组分离株中观察到更高水平的抗真菌耐药性，这影响了治疗的有效性。血清学测试显示AECOPD组阳性结果的频率是前者的两倍。AECOPD患者的真菌群在数量和分类上都比对照组丰富，包括在人类中较少记录的物种。我们的研究证实，真菌菌群可能是影响COPD恶化和进展的潜在因素。

{"title":"Fungal microbiota in COPD patients during exacerbations","authors":"Weronika Gawor , Katarzyna Góralska , Sandra Galant , Sebastian Majewski , Wojciech Piotrowski , Joanna Miłkowska-Dymanowska , Justyna Kiszałkiewicz , Ewa Brzeziańska-Lasota","doi":"10.1016/j.mycmed.2025.101543","DOIUrl":"10.1016/j.mycmed.2025.101543","url":null,"abstract":"<div><div>Acute exacerbations of chronic obstructive pulmonary disease (COPD) results in increased mortality and can be triggered by a range of factors, including microorganisms. Very little studies have examined the role of fungi and fungal diversity in COPD patients. The aim of the study was to determine the role of <em>Candida</em> in COPD during an exacerbation. Oral swabs, sputum, feces and whole blood samples were collected from the AECOPD patients and control group. Mycological and serological analysis were performed. Yeast were statistically significantly more often isolated from the AECOPD group (97.06%) than from the control group (26.32%). 7 species were isolated from the AECOPD, and 3 from the control group. Dominated <em>Candida albicans</em> followed by <em>C. tropicalis</em>. α-diversity was much greater in AECOPD patients than in controls. β-diversity was also assessed. A much higher level of antimycotic resistance was observed in isolates from the AECOPD group, which affects the effectiveness of therapy. Serological tests showed twice the frequency of positive results in the AECOPD group. The mycobiota of AECOPD patients is numerically and taxonomically richer than controls, including species less frequently recorded in humans. Our research confirms that fungal mycobiota may be a potential factor influencing the development of exacerbations and progression of COPD.</div></div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"35 2","pages":"Article 101543"},"PeriodicalIF":2.2,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143636895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fungal Endocarditis in neonates: Case report and review of 79 cases (1983 to 2024) 新生儿真菌性心内膜炎79例报告（1983 ~ 2024年）

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale

Pub Date : 2025-03-07 DOI: 10.1016/j.mycmed.2025.101542

Natália Daiane Garoni Martins , Beatriz dos Santos Bezerra , Cinthya Alves Esteves , Luana Rossato

Purpose

Fungal endocarditis in neonates poses a significant clinical challenge, with limited comprehensive data available. The aim of this study was describe a case report and further characterize demographic and clinical aspects of fungal endocarditis in neonates.

Methods

We present, a case report of a very low birth weight infant with fungal endocarditis. We also conducted a thorough analysis of 79 documented clinical cases, exploring demographics, clinical characteristics, treatment strategies, and outcomes.

Results

The temporal distribution revealed varied trends over the years. The United States had the highest case count, followed by India, Turkey, and Israel. Prematurity was predominant, with extremely low birth weight neonates being most affected. Congenital malformations were present in 10.2 % of cases. Surgical interventions, particularly for vegetative mass removal, were common. Candida albicans was the primary pathogen, followed by Candida parapsilosis. Catheter use was strongly associated with the majority of cases. The overall mortality rate was 38 %. Higher mortality was observed in neonates receiving monotherapy compared to those on combination therapy. Mortality was also significantly higher in neonates with prior bacteremia or fungemia and in those receiving antibiotic therapy without confirmed bacteremia. Conversely, postoperative mortality associated with surgery was 36.4 %, slightly lower than the overall mortality rate, suggesting that surgery may not represent an increased risk.